<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gadobutrol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gadobutrol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gadobutrol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8632" href="/d/html/8632.html" rel="external">see "Gadobutrol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11952" href="/d/html/11952.html" rel="external">see "Gadobutrol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F13478027"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Nephrogenic systemic fibrosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of gadolinium-based contrast agents in these patients unless the diagnostic information is essential and not available with noncontrasted magnetic resonance imaging (MRI) or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.</p>
<p style="text-indent:-2em;margin-left:2em;">The risk for NSF appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>) or acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:2em;">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at highest risk for NSF, do not exceed the recommended gadobutrol dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12765549"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gadavist</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868894"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Gadovist</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F26146979"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Diagnostic Agent</span>;</li>
<li>
<span class="list-set-name">Gadolinium-Containing Contrast Agent</span>;</li>
<li>
<span class="list-set-name">Radiological/Contrast Media, Nonionic (High Osmolality)</span>;</li>
<li>
<span class="list-set-name">Radiological/Contrast Media, Paramagnetic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F56488957"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging:</b> CNS imaging and supra-aortic or renal artery angiography: Term neonates: IV: 0.1 mmol/kg (0.1 mL/kg); may begin imaging immediately after administration.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F13362717"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging:</b> CNS imaging and supra-aortic or renal artery angiography: Infants, Children, and Adolescents: IV: 0.1 mmol/kg (0.1 mL/kg); may begin imaging immediately after administration.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112162"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate kidney impairment: Dose adjustment is not recommended; however, use with caution. Risk for nephrogenic systemic fibrosis (NSF) development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: There are no pediatric-specific recommendations; based on experience in adult patients, in patients already receiving hemodialysis, consider prompt hemodialysis following exposure. Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11350296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11350296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: There are no pediatric-specific recommendations, based on adult experience, peritoneal dialysis is likely less efficient at clearing gadolinium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9653466','lexi-content-ref-17213364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9653466','lexi-content-ref-17213364'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51112163"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on exclusive renal excretion of gadobutrol, dose adjustment in hepatic impairment is likely unnecessary.</p></div>
<div class="block doa drugH1Div" id="F5175443"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8632" href="/d/html/8632.html" rel="external">see "Gadobutrol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b> IV:</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Breast malignancy imaging, CNS imaging, and supra-aortic or renal artery angiography: 0.1 mmol/kg (0.1 mL/kg); may begin imaging immediately after administration</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiac imaging: 0.05 mmol/kg (0.05 mL/kg) at peak pharmacological stress, followed by 0.05 mmol/kg (0.05 mL/kg) at rest</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Breast malignancy imaging: Usual dose: 0.1 mmol/kg (0.1 mL/kg); maximum: 0.3 mmol/kg (0.3 mL/kg)</p>
<p style="text-indent:-2em;margin-left:4em;">CNS imaging:</p>
<p style="text-indent:-2em;margin-left:6em;">General imaging: 0.1 mmol/kg (0.1 mL/kg); if needed, a second dose of 0.1 to 0.2 mmol/kg (0.1 to 0.2 mL/kg) may be repeated once within 30 minutes of the first dose</p>
<p style="text-indent:-2em;margin-left:6em;">Exclusion of metastatic or recurrent tumors: 0.3 mmol/kg (0.3 mL/kg)</p>
<p style="text-indent:-2em;margin-left:6em;">Perfusion studies: 0.1 to 0.3 mmol/kg (0.1 to 0.3 mL/kg)</p>
<p style="text-indent:-2em;margin-left:4em;">CE-MRA:</p>
<p style="text-indent:-2em;margin-left:6em;">Imaging of a single field of view (FOV):</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &lt;75 kg: 7.5 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≥75 kg: 10 mL</p>
<p style="text-indent:-2em;margin-left:6em;">Imaging &gt;1 FOV:</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &lt;75 kg: 15 mL</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≥75 kg: 20 mL</p>
<p style="text-indent:-2em;margin-left:4em;">Renal imaging: Usual dose: 0.1 mmol/kg (0.1 mL/kg); maximum: 0.3 mmol/kg (0.3 mL/kg)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991467"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure. Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11350296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11350296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9653466','lexi-content-ref-17213364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9653466','lexi-content-ref-17213364'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988793"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, based on exclusive renal excretion of gadobutrol, dose adjustment in hepatic impairment is likely unnecessary.</p></div>
<div class="block adr drugH1Div" id="F5174709"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, maculopapular rash, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, anaphylactic shock, angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell, dizziness, feeling hot, loss of consciousness, malaise, paresthesia, seizure, sensation of cold</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Bordel Gómez 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrogenic systemic fibrosis (Wollanka 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome (Park 2015)</p></div>
<div class="block coi drugH1Div" id="F5174319"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Severe hypersensitivity reactions to gadobutrol or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F5174320"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: May be a vesicant (higher osmolar contrast agents and/or higher volumes are associated with a higher risk). Ensure proper needle or catheter placement prior to and during administration. Monitor infusion site. Avoid extravasation; local tissue irritation may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gadolinium retention: Gadolinium is retained for months or years in brain, bone, skin, and other organs (kidney, liver, spleen); the highest concentration and longest duration have been found in the bone. Linear GBCAs (gadodiamide and gadoversetamide &gt; gadoxetate disodium, gadopentetate dimeglumine, and gadobenate dimeglumine) result in more retention than macrocyclic GBCAs (gadoterate meglumine, gadobutrol, and gadoteridol). Pathologic and clinical consequences of gadolinium retention in skin and other organs have been established in patients with impaired renal function; there also have been rare reports of pathologic skin changes in patients with normal renal function. Consequences of gadolinium retention in the brain or in patients with normal renal function have not been established. Patients with normal renal function that may be at higher risk for gadolinium retention include: patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions; take GBCA retention characteristics into consideration for these patients. Minimize repetitive GBCA imaging studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylactic and other hypersensitivity reactions (some fatal) have occurred (with mild to severe cardiovascular, respiratory or dermatologic involvement). Reactions typically occur within 30 minutes of administration; however, delayed reactions may also occur (up to several days following administration). Appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Use with caution in patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrogenic systemic fibrosis (NSF): <b>[US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure increases the risk for NSF in patients with renal impairment; avoid use unless GBCA-enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>).</b> The risk for NSF appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration. If NSF occurs, report to manufacturer or the Food and Drug Administration (FDA).</p>
<p style="text-indent:-2em;margin-left:4em;">All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, chronic hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of gadolinium agents, generally within 48 hours following administration. In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold. Injectable antiseizure agents should be readily available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Scan interpretation: Certain lesions may not appear with contrast-enhanced scan that do appear with noncontrast imaging; use caution when interpreting. Overestimation of extent of malignant disease in MRI of the breast has occurred in up to 50% of patients. A negative MRA study alone should not be used to rule out significant stenosis; performance of MRA for detecting arterial segments with significant stenosis (&gt;50% renal, &gt;70% supra-aortic) has not been shown to exceed 55%.</p></div>
<div class="block foc drugH1Div" id="F12765550"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gadavist: 1 mmol/mL (2 mL, 7.5 mL, 10 mL, 15 mL, 30 mL, 65 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mmol/mL (2 mL, 7.5 mL, 10 mL, 15 mL, 30 mL, 65 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gadavist: 7.5 mmol/7.5 mL (7.5 mL); 10 mmol/10 mL (10 mL); 15 mmol/15 mL (15 mL)</p></div>
<div class="block geq drugH1Div" id="F5174310"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16324143"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gadavist Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mmol/mL (per mL): $9.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gadobutrol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mmol/mL (per mL): $6.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Gadavist Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5MMOL/7.5ML (per mL): $10.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mmol/10 mL (per mL): $10.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mmol/15 mL (per mL): $10.52</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868895"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gadovist: 1 mmol/mL (15 mL)</p></div>
<div class="block adip drugH1Div" id="F53569536"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Contrast agents are generally classified as high-osmolar (≥1400 mOsm/kg), low-osmolar (780 to 800 mOsm/kg), or iso-osmolar (~300 mOsm/kg) relative to plasma osmolarity (~285 mOsmol/kg).</p></div>
<div class="block admp drugH1Div" id="F52614253"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Do not administer other medications in the same IV line simultaneously.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Central nervous system imaging:</b> Administer as an IV injection, manually or by power injector, at a rate of ~2 mL/second, followed by a NS flush. Post contrast MRI can commence immediately following contrast administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Supra-aortic or renal artery angiography:</b> Administer manually or by power injector, followed by a NS flush. Image acquisition should coincide with peak arterial concentration, which varies among patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); elevate extremity.</p></div>
<div class="block adm drugH1Div" id="F5175447"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Do not administer other medications in the same IV line simultaneously.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast malignancy imaging:</b> Administer as an IV bolus by power injector, followed by NS flush. Post contrast MRI can commence immediately following contrast administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac imaging:</b> Administer as 2 separate IV bolus injections by power injector, at a rate of ~4 mL/second; follow each injection by a 20 mL NS flush at the same rate. If concomitantly administering a continuous infusion of pharmacologic stress agent, administer gadobutrol through a separate IV line in the contralateral arm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS imaging:</b> Administer as an IV injection, manually or by power injector, at a rate of ~2 mL/second, followed by a NS flush. Post contrast MRI can commence immediately following contrast administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Supra-aortic or renal artery angiography:</b> Administer by power injector, at a rate of ~1.5 mL/second, followed by a 30 mL NS flush at the same rate. Image acquisition should coincide with peak arterial concentration, which varies among patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> For perfusion studies, automatic injector is recommended at an infusion rate of 3 to 5 mL/second</p>
<p style="text-indent:-2em;margin-left:2em;">May be a vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>); other sources suggest its utility in extravasation management for inoperable cases with compartment syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If using hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Dose varies based on the size of infiltration; inject a total of 5 to 250 units (~100 mL contrast reabsorbed per 15 units of hyaluronidase) around the site of extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F5174739"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). If freezing occurs; bring to room temperature before use; do not use unless solution is clear, colorless to pale yellow. Discard any unused drug. Pharmacy bulk package must be discarded within 24 hours after opening in a sterile environment.</p></div>
<div class="block meg drugH1Div" id="F51427237"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication;</p>
<p style="text-indent:-2em;margin-left:4em;">Gadavist: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F201277s020lbl.pdf%23page%3D42&amp;token=QSlNci0ReIwkMB%2By%2FEoCGIhCnjpPIE94tInb9au%2B7NdtzW%2Ftmfr3pBMBgeOtEuse2exdSNtmdHyiFBHub5zTdCMWkZsCS0xiCC82VI7qA1ElGB26S1ucRLR1WtLSpfIW&amp;TOPIC_ID=134757" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201277s020lbl.pdf#page=42</a></p></div>
<div class="block usep drugH1Div" id="F53570212"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">MRI to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the CNS (FDA approved in all ages); MRI to evaluate known or suspected supra-aortic or renal artery disease (FDA approved in all ages); contrast medium for use with MRI to assess the presence and extent of malignant breast disease (FDA approved in adults); cardiac MRI (CMRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement with known or suspected coronary artery disease (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F5174304"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gadavist may be confused with Magnevist</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gadovist [Canada and multiple international markets] may be confused with Vasovist brand name for gadofosveset [Hungary, Turkey]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299376"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F5174716"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F5174315"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Gadolinium-based contrast agents may cross the placenta (ACOG 723 2017; ACR 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients may be at increased risk for gadolinium retention. Use of gadolinium-based contrast agents in pregnancy is controversial and should be limited. A gadolinium-based contrast agent with MRI may be considered for use in pregnancy if it will significantly improve diagnostic performance and is expected to improve fetal or maternal outcome (ACOG 723 2017). In addition, use should only be considered if information needed from the MRI study cannot be acquired without using a contrast agent and cannot be deferred until after delivery. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2021).</p></div>
<div class="block mopp drugH1Div" id="F53570203"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function; signs of hypersensitivity (during and for several hours after procedure); short- and long-term monitoring of signs and symptoms of nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye); monitor for signs/symptoms of extravasation.</p></div>
<div class="block pha drugH1Div" id="F5175439"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gadobutrol is a gadolinium-containing, nonionic paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device. </p></div>
<div class="block phk drugH1Div" id="F5174740"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Rapid into extracellular space</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal renal function: ~1.5 to 2 hours; severe renal dysfunction (CrCl &lt;30 mL/minute):  17.6  hours (mean)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;90% as unchanged drug); feces (negligible)</p></div>
<div class="block phksp drugH1Div" id="F51196082"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The elimination half-life was 5.8 hours in mild-to-moderately impaired patients (CrCl 30 to 80 mL/minute) and 17.6 hours in severely impaired patients not on dialysis (CrCl &lt;30 mL/minute). The mean AUC in patients with healthy renal function was 1.1 mmol•h/L compared with 4 mmol•h/L in patients with mild-to-moderate renal impairment, and 11.5 mmol•h/L in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC was slightly higher and clearance slightly lower in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5175456"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gadograf</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gadograf | Gadovist</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gadovistauto</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gadobrix | Gadovision | Gadovist</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Gadavist</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gadovist</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. Erratum in: <i>Obstet Gynecol</i>. 2018;132(3):786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. 2023. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed May 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.2">
<a name="ACR.2"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. Version 2021. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed May 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi: 10.1007/s00330-002-1630-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29341190">
<a name="29341190"></a>Bordel Gómez MT, Martín García C, Meseguer Yebra C, Zafra Cobo MI, Cardeñoso Álvarez ME, Sánchez Estella J. First case report of acute generalized exanthematous pustulosis (AGEP) caused by gadolinium confirmed by patch testing. <i>Contact Dermatitis</i>. 2018;78(2):166-168. doi:10.1111/cod.12878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/29341190/pubmed" id="29341190" target="_blank">29341190</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gadavist (gadobutrol) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference">
                  Gadavist imaging bulk package (gadobutrol) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference">
                  Gadovist (gadobutrol) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653466">
<a name="9653466"></a>Joffe P, Thomsen HS, and Meusel M, "Pharmacokinetics of Gadodiamide Injection in Patients With Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis," <i>Acad Radiol</i>, 1998, 5(7):491-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/9653466/pubmed" id="9653466" target="_blank">9653466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17213364">
<a name="17213364"></a>Kuo PH, Kanal E, Abu-Alfa AK, et al, "Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis," <i>Radiology</i>, 2007, 242(3):647-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/17213364/pubmed" id="17213364" target="_blank">17213364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: A Hazard of Intravenous Therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11350296">
<a name="11350296"></a>Okada S, Katagiri K, Kumazaki T, et al, “Safety of Gadolinium Contrast Agent in Hemodialysis Patients,” <i> Acta Radiol</i>, 2001, 42(3):339-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/11350296/pubmed" id="11350296" target="_blank">11350296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26069143">
<a name="26069143"></a>Park J, Byun IH, Park KH, Lee JH, Nam EJ, Park JW. Acute respiratory distress syndrome after the use of gadolinium contrast media. <i>Yonsei Med J</i>. 2015;56(4):1155-1157. doi:10.3349/ymj.2015.56.4.1155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/26069143/pubmed" id="26069143" target="_blank">26069143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633726">
<a name="22633726"></a>Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/22633726/pubmed" id="22633726" target="_blank">22633726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19767635">
<a name="19767635"></a>Wollanka H, Weidenmaier W, Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. <i>Nephrol Dial Transplant</i>. 2009;24(12):3882-3884. doi:10.1093/ndt/gfp494<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadobutrol-pediatric-drug-information/abstract-text/19767635/pubmed" id="19767635" target="_blank">19767635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-zenk">
<a name="zenk"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 134757 Version 35.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
